News from mirati therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 10, 2021, 14:35 ET Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its...

Mar 31, 2021, 07:30 ET Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new...

Mar 10, 2021, 16:39 ET Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the...

Feb 25, 2021, 16:15 ET Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full...

Feb 18, 2021, 16:15 ET Mirati Therapeutics To Present At Upcoming Healthcare Conferences

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences. Friday,...

Feb 10, 2021, 07:00 ET MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today...

Feb 04, 2021, 16:30 ET Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the ...

Jan 04, 2021, 17:19 ET Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare...

Nov 23, 2020, 16:30 ET Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the ...

Nov 05, 2020, 16:30 ET Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the ...

Nov 04, 2020, 16:15 ET Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended...

Oct 30, 2020, 17:09 ET Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of...

Oct 27, 2020, 20:04 ET Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a...

Oct 26, 2020, 16:46 ET Mirati Therapeutics Announces Proposed Public Offering of Common Stock

Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of...

Oct 25, 2020, 10:45 ET Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant...

Oct 15, 2020, 16:30 ET Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), ...

Sep 18, 2020, 08:00 ET Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study ...

Sep 17, 2020, 08:01 ET Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor

Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, ...

Sep 03, 2020, 16:30 ET Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will participate in a fireside chat at the...

Aug 06, 2020, 16:15 ET Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the ...

Jun 05, 2020, 09:00 ET Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41st Annual Goldman Sachs...

May 18, 2020, 16:15 ET Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief...

May 15, 2020, 09:00 ET Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the...

May 07, 2020, 16:05 ET Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates